Abstract
Prophylactic treatment of frequent episodic and chronic migraine is often unsuccessful. In recent years, the therapeutic procedures have focused on the particular segments of the pathophysiological chain of migraine.
Calcitonin Gene-Related Peptide (CGRP) is a key peripheral and central agent. Data emerging from trials with monoclonal antibodies (mAb) suggest that this specific blockade of the CGRP pathway may provide an effective and safe novel preventive therapeutical approach in migraine.